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Inflammation and thrombosis are two responses that are linked through a number of 
mechanisms, one of them being the complement system. Various proteins of the 
complement system interact specifically with platelets, which, in turn, activates them and 
promotes thrombosis. In this paper, we show that the converse is also true: activated 
platelets can activate the complement system. As assessed by flow cytometry and 
immunoblotting, C3 deposition increased on the platelet surface upon cell activation with 
different agonists. Activation of the complement system proceeded to its final stages, which 
was marked by the increased generation of the anaphylotoxin C3a and the C5b-9 complex. 
We identified P-selectin as a C3b-binding protein, and confirmed by surface plasmon 
resonance binding that these two proteins interact specifically with a dissociation constant 
of 1 
 
 
 
M. Using heterologous cells expressing P-selectin, we found that P-selectin alone is 
sufficient to activate the complement system, marked by increases in C3b deposition, C3a 
generation, and C5b-9 formation. In summary, we have found that platelets are capable of 
activating the complement system, and have identified P-selectin as a receptor for C3b 
capable of initiating complement activation. These findings point out an additional 
mechanism by which inflammation may localize to sites of vascular injury and thrombosis.
 
Complement is a multi-component system that
involves several plasma and cell-expressed pro-
teins, and has been conserved throughout evo-
lution. Although recognized primarily as an
important  part of innate immunity, comple-
ment has adopted additional functions in differ-
ent organisms. The complement system medi-
ates cell–cell interactions in many physiological
processes, such as hematopoiesis, organogenesis,
and in reproduction (1). For these functions to
be executed, the complement system requires
activation that is marked by the formation of the
C3 convertase complex on the surface of target
cells. This convertase cleaves large quantities of
C3 into C3b, the main effector of complement,
and C3a, a potent mediator of inflammation re-
leased into the medium. C3b and its degradation
products fixed on target cells functions as op-
sonins, thereby marking the cell for destruction
by phagocytes attracted by anaphylotoxins (C3a
and C5a). Also, C3b on the cell surface partici-
pates in the serial activation of complement pro-
teins (C5–C9) that polymerize and form the
C5b-9 complex, also known as the membrane
attack complex. If an adequate number of C5b-9
complexes form, the target cell is destroyed.
Several negative regulatory proteins exist
to prevent uncontrolled activation of the com-
plement system and widespread tissue damage.
A deficiency in the negative regulators of
complement leads to excessive complement
activation, as observed in paroxysmal nocturnal
hemoglobinuria (PNH) and atypical or familial
hemolytic uremic syndrome (HUS). Interest-
ingly, both of these diseases are characterized
by thrombosis. Studies suggest that the mecha-
nisms of thrombosis in PNH and familial HUS
are related to platelet activation induced by
complement activation. Patients with PNH
were found to have baseline platelet hyperre-
activity, as evidenced by increased P-selectin
expression (2). Also, mice deficient in the neg-
ative regulator of complement, CD59b, ex-
hibit platelet hyperreactivity (3). Much ex-
perimental evidence supports the notion that
complement activation leads to platelet activa-
tion. Several proteins of the complement sys-
tem, including C3 and C5–C9, were shown to
potentiate thrombin-induced platelet secretion
and aggregation (4). The anaphylotoxin C3a
was found to induce platelet activation and ag-
gregation (5). Also, treatment of platelets with
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sublytic concentrations of C5b-9 caused transient membrane
depolarization (6), granule secretion (7), generation of pro-
coagulant platelet microparticles (8), and translocation of
phosphatidylserine to the outer membrane leaflet (9, 10)
Collectively, these studies make the case that the comple-
ment system may serve as a link between inflammation and
thrombosis, and reveal specific interactions between comple-
ment proteins and platelets.
We determined whether a reciprocal interaction also ex-
ists, whereby platelets can activate complement. Here, we
show that upon activation, platelets activate the complement
system, which proceeds to its final stages marked by the for-
mation of the C5b-9 complex. We have also identified P-selec-
tin expressed on activated platelets as a receptor for C3b,
thus linking thrombosis and local activation of the comple-
ment system on platelets.
 
RESULTS
C3 deposition on activated platelets
 
We determined whether complement activation marked by
C3 deposition increased on shear-activated platelets. We
subjected platelets in plasma to shear rates of either 0, 1,000,
or 10,000 s
 
 
 
1
 
 for 1 min; rates that would be expected in
blood stasis, arterioles, and in stenotic vessels, respectively.
The amount of C3 deposition on platelets increased with in-
creasing shear rates (Fig. 1 A). Under static conditions, plate-
lets contained appreciable quantities of C3, an amount that
increased when platelets were subjected to a shear rate of
1000 s
 
 
 
1
 
, and which was greatest at a shear of 10,000 s
 
 
 
1
 
.
These differences were specific, as the amount of the platelet
protein, 
 
 
 
-actin, was similar in the three samples.
We determined whether C3 is also deposited on plate-
lets activated with other agonists. Compared with unstimu-
lated platelets, platelets activated with either ADP or
thrombin receptor–activating peptide (TRAP) had a larger
amount of associated C3 (Fig. 1 B). Similar amounts of the
platelet receptor GP Ib
 
 
 
 in the three samples indicated
equal protein loading.
 
C3a generation in activated platelets
 
As an additional test of whether platelets activate comple-
ment, we examined generation of C3a, which is the released
cleavage product of C3. Platelets (250 
 
 
 
 10
 
3
 
/
 
 
 
l) subjected
to shear rates of 1000, 5000, and 10,000 s
 
 
 
1
 
 for 60 s gener-
ated on average 15, 46, and 245 ng C3a/ml platelet-rich
plasma (PRP), respectively, than platelets in static conditions
(Fig. 2 A). We also tested the effect of agonists on C3a gen-
eration by platelets. Platelets that were activated with either
collagen or TRAP in the presence of 1 ml of plasma gener-
ated on average 169 and 89 ng C3a, respectively, which was
Figure 1. Deposition of C3 on activated platelets. Platelet-rich 
plasma was (A) subjected to different shear rates for 60 s, or (B) activated 
with different agonists. Platelets were then pelleted, washed with TBS 
buffer, lysed in reducing SDS sample buffer, and subjected to PAGE and 
Western blotting for C3. The same membranes was stripped and probed 
for  -actin or GP Ib  as loading controls. These results are representative 
of three experiments.
Figure 2. Activation of complement on activated platelets. 
(A) Generation of C3a by activated platelets. 1 ml PRP was stimulated with 
either 20  M ADP, 10  M TRAP, 20  g/ml collagen, or with different shear 
rates for 60 s. Platelets were pelleted, and C3a levels were measured in the 
plasma supernatant using ELISA. The plasma of a suspension of resting 
platelets served as the controls. n   4; *, P   0.05. (B) Formation of the 
C5b-9 complex on activated platelets: platelet-rich plasma (PRP) was 
stimulated with either 20  M ADP, 10  M TRAP, or 10,000 s 1   60-s 
shear. Platelets were then probed by flow cytometry for the presence of the 
C5b-9 complex using a rabbit anti–C5b-9 neoepitope. Baseline fluorescence 
was set using nonimmune rabbit IgG and a secondary FITC-conjugated 
antibody. These results are representative of four experiments. 
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more than unstimulated platelets (Fig. 2 a). In contrast, stim-
ulation of platelets with ADP did not significantly affect C3a
generation. We excluded the possibility that contaminating
neutrophils contributed to C3a generation by adding in-
creasing counts of autologous neutrophils (from 500 to 5 
 
 
 
10
 
5
 
 neutrophils) to a constant number (2 
 
 
 
 10
 
5
 
) of platelets
in plasma, which were subsequently stimulated with col-
lagen. We found no differences in the amount of C3a gener-
ation throughout the entire range of neutrophil counts tested
(unpublished data).
 
C5b-9 complex forms on activated platelets
 
We investigated whether complement activation on the
platelet surface proceeded to its final stages, which is marked
by the formation of the membrane attack complex (C5b-9
complex). Compared with resting platelets, platelets acti-
vated with either 20 
 
 
 
M ADP, 5 
 
 
 
M TRAP, or shear ex-
hibited greater amounts of C5b-9 on their surface, relative to
unstimulated platelets (Fig. 2 B).
 
C3b binds to activated platelets
 
To study the molecular events involved in the initiation and
propagation of the complement activation on the surface of
platelets, we measured the deposition of FITC-conjugated
C3b on resting and TRAP-activated washed platelets. On
average, 
 
 
 
10% of unstimulated platelets bound C3b-FITC.
However, there was a marked increase in the binding of
C3b-FITC when platelets were stimulated with TRAP,
with 
 
 
 
65% of platelets becoming positive for C3b-FITC
(Fig. 3 A). As an additional control, we determined the
binding of C3b-FITC to the monocytic cells, THP-1,
which are known to constitutively express CR1 (11), a re-
ceptor for C3b, and CR2 (12). On average, 77% of THP-1
cells bound C3b-FITC (Fig. 3 B).
To determine whether C3b was binding a platelet pro-
tein, we removed surface proteins from activated platelets
using a low concentration of protease K (50 
 
 
 
g/ml). After
extensive washing, platelets were probed with FITC-labeled
C3b. Removal of surface proteins abolished binding of C3b
to the surface of activated platelets (Fig. 3 C). As assessed
by global protein tyrosine phosphorylation profiles (13),
TRAP-activated platelets that were subsequently treated
with protease K maintained their activated state (unpub-
lished data).
 
P-Selectin mediates C3b binding to activated platelets
 
Platelets express P-selectin upon activation, and P-selectin
contains nine sushi domains, which are a common structural
motif present in many complement-binding proteins, such as
complement receptors (CR) 1 and 2. We therefore examined
whether P-selectin is the C3b receptor on activated platelets.
We investigated the effect that an anti–P-selectin antibody
had on C3b binding to activated platelets. Treatment of
TRAP-activated platelets with an anti–P-selectin antibody
significantly reduced the amount of deposited C3b (Fig. 3 D).
 
P-Selectin mediates the adhesion of activated platelets to 
C3b under flow conditions
 
To test the interaction between P-selectin and C3b under
flow conditions, we used a flow chamber apparatus and per-
fused TRAP-activated platelets over immobilized C3b at a
constant shear stress of 2 dynes/cm
 
2
 
. Activated platelets
readily formed aggregates over the C3b as early as 20 s of
perfusion time, developing into large platelet thrombi within
2 min. This interaction was specific, because activated plate-
lets did not attach on an albumin-coated surface (unpub-
lished data). Pre-treatment of the platelets with an anti–
P-selectin antibody almost completely eliminated thrombus
formation, confirming that the interaction between activated
platelets and C3b is mediated by P-selectin (Fig. 4). In con-
trast, pretreatment of platelets with an antibody against the
Figure 3. Binding of C3b to activated platelets. (A) Binding of C3b to 
the surface of activated platelets was measured by flow cytometry using 
FITC-conjugated purified C3b. Washed platelets, either resting or stimulated 
with 5  M TRAP, were probed with FITC-C3b. Background fluorescence was 
set using BSA-FITC. (B) Binding of C3b-FITC to the monocytic cells, THP-1, 
which constitutively express the complement receptor CR1. (C) Cleavage of 
surface proteins inactivated using 50  g/ml protease K abrogates the bind-
ing of FITC-conjugated C3b. (D) Binding of FITC-C3b to TRAP-activated plate-
lets was inhibited by treating the platelets with anti–P-selectin antibody. 
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platelet receptor GPIb
 
 
 
 did not inhibit the binding of acti-
vated platelets to C3b (unpublished data).
 
C3b binds to Chinese hamster ovary (CHO) cells expressing 
P-selectin (CHO-P)
 
We measured the binding of plasma C3 to CHO and CHO-P
cells. We incubated the cells in fresh human plasma and
measured the amount of deposited C3 using a polyclonal
anti-C3 antibody and flow cytometry. Compared with
CHO cells, CHO cells expressing P-selectin bound more
plasma C3 (Fig. 5 A). To further examine P-selectin as a
C3b-binding protein in an isolated system, we measured the
binding of FITC-conjugated C3b to CHO-P cells. Com-
pared with CHO cells, CHO-P cells bound much more
C3b: 87% of CHO-P cells were positive for C3b-FITC
compared with 2% of CHO cells. These differences in C3b
binding also resulted in a 7.7-fold greater C3b-FITC mean
fluorescence intensity (MFI) in CHO-P compared with
control CHO cells (MFI, 476 vs. 62 in CHO-P and CHO
cells, respectively; 
 
n
 
 
 
  
 
5, P 
 
  
 
0.01; Fig. 5 B).
C3b binding to P-selectin was partially dependent on
calcium and magnesium. In the absence of these cations,
binding of C3b to P-selectin was 
 
 
 
5.7-fold greater than to
cells expressing a control protein (the 
 
 
 
IX subunits of the
GPIb–IX-V complex). However, in the presence of 2 mM
CaCl
 
2
 
, 1 mM MgCl
 
2
 
, or 2 mM CaCl
 
2
 
 
 
 
 
 1 mM MgCl
 
2
 
, the
binding of C3b to P-selectin increased by 
 
 
 
33%, 55%, and
63%, respectively, compared with the sample without cal-
cium or magnesium (Fig. 5 C). For these experiments, we
used two negative controls: first, CHO-P cells incubated
with FITC-conjugated BSA; and second, binding of C3b-
FITC to CHO cells expressing the 
 
 
 
IX subunits of the
platelet GPIb–IX-V complex. Because GP
 
 
 
IX is expressed
on the platelet surface, but has no known ligand-binding
properties (14), it served as a negative control for C3b binding.
By flow cytometry, CHO-
 
 
 
IX cells did not bind C3b-
Figure 4. P-Selectin mediates the interaction between activated 
platelets and C3b. TRAP-activated platelets were perfused over C3b 
immobilized on a glass coverslip (30  g/ml) at a constant shear stress of 
2 dyne/cm2 in a parallel plate flow chamber. Thrombus formation was 
visualized and recorded over 2 min. Treatment of platelets with an anti–
P-selectin polyclonal antibody (25  g/ml) abolished platelet adhesion to 
the immobilized C3b. Activated platelets failed to adhere to immobilized 
BSA. All the images are taken with 20  magnification.
Figure 5. Binding of C3b to P-selectin. (A) Binding of plasma C3 to 
CHO-P and CHO cells was studied by incubating the cells in platelet-poor 
plasma for 30 min at 37 C. Cells were then probed with goat anti-C3 anti-
serum and a secondary FITC-anti–goat antibody. Baseline fluorescence 
was set using normal goat serum (NGS) and the secondary antibody. 
(B) Binding of FITC-labeled purified C3b was determined in CHO and CHO-P 
by flow cytometry. (C) The effect of calcium and magnesium on the bind-
ing of C3b to P-selectin expressed on CHO cells (CHO-P) was assessed by 
flow cytometry. Binding of FITC-labeled bovine serum albumin (BSA-FITC) 
to P-selectin, and binding of C3b-FITC to cells expressing the  IX subunit 
of the GPIb–IX-V complex served as negative controls. n   4; *, P   0.05. 
(D) Surface plasmon resonance binding studies of the interaction between 
purified C3b and recombinant ectodomain of P-selectin. Binding curves of 
P-selectin were obtained perfusing different concentrations of purified 
C3b over the P-selectin surface, as described in the Materials and methods. 
Dissociation constant (Kd) obtained for binding of C3b to P-selectin was 
1.0  M. RU, resonance units. 
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FITC above a control set with equal concentrations of the
control protein, BSA-FITC (unpublished data).
 
Surface plasmon resonance analysis of the C3b–P-selectin 
interaction
 
To assess the specificity of the P-selectin–C3b interaction,
we used surface plasmon resonance analysis in which the
P-selectin was immobilized on a CM5 chip. Various concen-
trations of C3b ranging from 0.5 to 5.0 
 
 
 
M were perfused
over the immobilized P-selectin. Analysis of the sensograms
yielded a 
 
K
 
d
 
 of 1 
 
 
 
M (Fig. 5 D).
 
P-Selectin activates the complement system
 
C3a generation.
 
The data described before identified
P-selectin as a C3b-binding protein. Therefore, we deter-
mined whether P-selectin is also capable of activating the
complement system. We tested C3a generation in CHO and
CHO-P cells by incubating them for 1 h in normal, cell-free
plasma. Cells expressing P-selectin generated a significant
77% more C3a than did mock-transfected cells (1,240 vs.
697 ng/ml; Fig. 6 A).
 
C5b-9 formation.
 
We next determined whether the for-
mation of the terminal complement complex (the C5b-9
complex), was greater on CHO-P cells than on CHO-cells.
Cells were incubated in cell-free plasma for 1 h, at 37
 
 
 
C, and
C5b-9 formation was subsequently measured by flow cy-
tometry. Compared with control CHO-cells, cells express-
ing P-selectin demonstrated an increase in the number of
C5b-9 complexes formed on their surfaces (Fig. 6 B).
 
C3 convertase and P-selectin.
 
To determine whether
factor B is necessary for P-selectin–expressing cells to acti-
vate complement, we reconstituted the common pathway of
the complement system, with or without factor B, and mea-
sured the ability of CHO-P cells to generate C3a as a surro-
gate of complement activation. CHO-P cells, but not con-
trol CHO cells, generated significantly greater amounts of
C3a in the presence of factor B than in its absence (1,780 vs.
1,093 ng/ml, 
 
n
 
 
 
  
 
4, P 
 
  
 
0.01) (Fig. 6 C).
 
DISCUSSION
 
Thrombosis and inflammation coexist in many physiologic
and pathologic processes. Several mechanisms link these two
processes, such as the binding of leukocytes to activated
platelets at sites of thrombosis (15), the release of proinflam-
matory chemokines and cytokines by activated platelets (16–
18), and the cross-linking of CD40 and CD40L between
platelets and leukocytes (19). Working together, these two
systems ensure that the tissue repair responses localize to sites
of injury, where hemostasis has taken place.
Activation of the complement system during inflamma-
tion is likely to be a significant contributor to the prothrom-
botic drive. The direct products of complement activation,
the membrane attack complex C5b-9, and the anaphylotox-
ins C3a and C5a, have been shown to activate platelets (5)
and promote coagulation by stimulating phosphatidylserine
exposure (9, 10). Thus, it is not surprising that dysregulated
complement activation, as observed in PNH and HUS, is
characterized clinically by thrombotic events. Conversely, a
deficiency in complement proteins may cause bleeding.
A setting in which complement-mediated platelet activa-
tion appears to play a major role is in immune complex-
induced glomerulonephritis. Localization of platelets in renal
glomeruli was shown to enhance inflammation and renal in-
jury in an animal model of glomerulonephritis (20). This
process seemed to depend on both complement proteins and
platelets, as depletion of either of them significantly reduced
kidney damage (20, 21).
Here, we show an additional link between thrombosis
and inflammation. We show that activated platelets are capa-
ble of activating the complement system through a process
that is partially dependent on P-selectin. Activated platelets
acquired significant amounts of C3 in the plasma, which is
an effect that occurred with a variety of agonists, including
Figure 6. P-Selectin activates the complement system. P-Selectin—
mediated activation of the complement system was studied in CHO cells. 
(A) CHO-P and CHO cells were incubated in PPP for 60 min. The cells were 
then sedimented, and C3a was measured in the plasma supernatant by 
ELISA. n   4; *, P   0.05. (B) Formation of the C5b-9 complex on CHO-P 
and CHO cells was measured by flow cytometry using a rabbit anti–C5b-9 
neoepitope. Baseline fluorescence was set using nonimmune rabbit IgG. 
These results are representative of four other experiments. (C) CHO and 
CHO-P cells were incubated in a reconstituted complement system, with 
or without factor B, for 60 min at 37 C. Cells were then sedimented and 
C3a was measured by ELISA in the supernatants. n   4; *, P   0.05. 
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TRAP, ADP, and shear. Lysates of unstimulated platelets
were found to contain significant quantities of C3. It is likely
that most of this C3 was stored in 
 
 
 
-granules, and that the
increase in C3 upon platelet activation represented deposi-
tion of the protein on the platelet surface. Interestingly, an
increase in C3 deposition was observed with increasing shear
rates, suggesting that the amount of deposited C3 is activa-
tion dependent. We confirmed that C3b binds to the surface
of activated platelets. Consistent with the activation of com-
plement on platelets, we found that platelets activated with
either shear or collagen generated 
 
 
 
200 ng/ml (
 
 
 
24 nM)
C3a above the baseline concentrations. Considering that
C3a is a potent anaphylotoxin capable of inducing inflam-
mation at concentrations in the nanomolar range (22), a
200-ng/ml increase in C3a concentrations is likely to be bi-
ologically important. The finding that activated platelets
generate C3a is consistent with the study of Weksler and
colleagues, who showed that activated platelets produced a
chemotactic stimuli for neutrophils in an in vitro model of
transendothelial migration (23).
We found that complement activation induced by acti-
vated platelets proceeded to its terminal phases, as evidenced
by the formation of the C5b-9 complex. Because C5b-9 it-
self can potently activate platelets, the finding that activated
platelets lead to C5b-9 formation points out a potentiating
mechanism for platelet activation and thrombosis that is me-
diated by the complement system.
Our studies shed light on the results reported by Polley
and Nachman in 1978, in which they found increased depo-
sition of C3 and C5b-9 on platelets stimulated with thrombin
(4). Because deposition of these complement proteins oc-
curred even in the absence of factor B or C2, the authors pos-
tulated that there was a distinct mechanism of complement
activation that was independent of the alternative and classic
pathways, which require factor B and C2, respectively. In the
model they postulated, a platelet protein, in conjunction with
thrombin, mediated the cleavage of C3 resulting in comple-
ment activation. Currently, it is known that platelets store
significant amounts of complement proteins within their
granules, and this explains why the absence of factor B or C2
in the platelet suspension would not prevent complement ac-
tivation. Our results indicate that complement activation by
stimulated platelets is not restricted to a particular agonist.
However, whether platelets stimulated by different platelet
agonists differ in their ability to activate the complement sys-
tem is not known and cannot be determined from our stud-
ies. Despite several experiments and using platelets from dif-
ferent donors, we found no significant differences in C3a
generation between resting and ADP-activated platelets. We
have no explanation for these findings but we believe that,
similar to collagen- and TRAP-activated platelets, ADP-
stimulated platelets are capable of activating the complement
system on their surfaces. This is evidenced by increased depo-
sition of C3b and increased formation of the C5b-9 complex
on ADP-stimulated platelets (Figs. 1 B and 2 B).
We investigated the mechanisms by which the surfaces of
activated platelets become permissive for complement acti-
vation. Our initial results indicated that the surface molecule
that bound C3b was activated or expressed only upon plate-
let activation, and, obviously, that it could bind complement
proteins. We hypothesized that P-selectin could be such a
protein, given that P-selectin expression in platelets is activa-
tion dependent (24). Furthermore, P-selectin has nine sushi
domains (25), which are a common structural motif in many
complement-binding proteins, such as CR1, CR2, and fac-
tor H (26, 27).
We found that P-selectin antibodies partially inhibited
the binding of FITC-conjugated C3b to activated platelets,
indicating that P-selectin is at least partly responsible for the
binding of C3b to activated platelets. By establishing P-selec-
tin as a specific C3b-binding protein, we showed that CHO-P
bound severalfold more C3b than did control CHO cells.
We obtained further evidence of a specific interaction be-
tween P-selectin and C3b by plasmon resonance binding,
revealing that these two proteins indeed interact with each
other with a 
 
K
 
d
 
 of 1 
 
 
 
M.
P-selectin not only bound C3b, but allowed the initia-
tion and propagation of complement activation on the cell
surface. CHO-P cells that were incubated in the plasma
bound more C3 and generated significantly greater quanti-
ties of C3a than did the control cells. Also, CHO-P cells that
were incubated in the plasma formed greater quantities of
the C5b-9 complex on their surface and generated more
C3a than control cells.
Collectively, our findings identify P-selectin as a C3b-
binding protein that is sufficient for activating the comple-
ment system via the formation of the C3 convertase complex
(C3bBb) on the surface of cells. We propose that, in the set-
ting of P-selectin expression, the complement system be-
comes activated, leading to inflammation and tissue injury.
The studies by Kyriakides et al. are consistent with this con-
jecture (28). These authors showed that soluble P-selectin
inhibited complement-induced muscle injury in murine
hindlimbs subjected to ischemia reperfusion. This inhibitory
effect of soluble P-selectin appeared to depend on the inter-
action between P-selectin and complement proteins, and to
require the sushi domains of P-selectin. Therefore, in light
of the findings of our studies, we believe that in the experi-
ments performed by Kyriakides and colleagues, the infused
P-selectin competed for C3b binding, diminishing the amount
of C3b deposited on the surfaces of cells.
In summary, we propose a model in which C3b gener-
ated by the spontaneous hydrolysis of C3 in the plasma,
binds to P-selectin the surface of activated platelets (Fig. 7).
C3b, together with factor B, forms the C3 convertase com-
plex cleaving large quantities of C3 into C3a and C3b. C3a
recruits leukocytes and induces inflammation, while C3b de-
posited on the surface of platelets leads to full activation of
the complement system and the formation of C5b-9 com-
plexes. Such a scheme would allow activation of the com- 
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plement system on activated platelets, thus inducing an in-
flammatory response localized to sites of thrombosis. Finally,
although we specifically examined complement activation
on the surface of platelets, we speculate that a similar phe-
nomenon occurs on the surface of activated endothelial cells.
If so, P-selectin may emerge as an important molecule for
localizing complement activation at sites of thrombosis and
inflammation.
 
MATERIALS AND METHODS
 
Platelet preparation.
 
Blood was drawn from healthy individuals into a
syringe containing 1/9 volume of 3.8% sodium citrate. PRP was obtained
by centrifuging the blood at 700 
 
g
 
 for 6 min. Platelet-poor plasma (PPP)
was prepared by centrifuging PRP at 2000 
 
g
 
 for 15 min. For some experi-
ments, platelets were washed once in tris-buffered saline (TBS; 50 mM
Tris-HCl and 0.9% NaCl, pH 7.4), in the presence of 5 ng/ml PGI
 
2
 
 to
avoid aggregation, and resuspended in Tyrode’s buffer (137 mM NaCl, 1.2
mM Hepes, 2.7 mM KCl, 0.04 mM NaH2PO4   H2O, and 5.6 mM glu-
cose, pH 7.4) containing 2 mM CaCl2. The platelet count in PRP and
washed platelet suspensions was adjusted to 250   103/ l using PPP and
buffer, respectively. All the studies performed on blood samples were ap-
proved by the Institutional Review Board of Baylor College of Medicine.
Platelet activation. Platelets were activated with different agonists. For ex-
periments in which platelets were activated with shear, 1 ml PRP was sub-
jected to a shear rate of either 0, 1,000, or 10,000 s 1 for 1 min in a cone
plate viscometer, prewarmed to 37 C (model RS1 visometer; Haake). In
other experiments, platelets in plasma were activated with either 20  M ADP
(Sigma-Aldrich), 5  M TRAP (Peninsula Laboratories), or 5  g/ml type-1
collagen (Helena Laboratories), stirring continuously for 20 min at 37 C.
Cell lines. CHO-P cells (provided by W. Smith, Baylor College of Medi-
cine, Houston, TX) were used to study the interaction between comple-
ment proteins and P-selectin. Mock-transfected CHO cells served as con-
trol cells. In the experiments assessing the effect of calcium and magnesium
on binding of C3b to P-selectin, we used CHO- IX cells (generated as in
reference 14) as an additional negative control. The monocytic cell line,
THP-1, was obtained from American Type Culture Collection.
Deposition of C3 on activated platelets and on heterologous cells.
Deposition of C3 on platelets or CHO-P cells was measured by Western
blotting and flow cytometry. For Western blotting, activated or resting plate-
lets from equal volumes of PRP were pelleted at 1,500 g for 10 min, washed
with TBS buffer, lysed in 8% SDS-reducing sample buffer, and subjected to
7.5% SDS-PAGE. Proteins were transferred onto a nitrocellulose membrane,
which was then blocked with nonfat milk (5 g/dl) and immunoblotted with
a goat anti–human C3 polyclonal antibody (Advanced Research Technolo-
gies) and with an HRP-conjugated secondary antibody (Zymed Laborato-
ries). We used Super signal Westpico chemiluminescent (Pierce Chemical
Co.) substrate to detect proteins. As a loading control, the blotted mem-
branes were treated with stripping buffer (Pierce Chemical Co.), and re-
probed with mAbs against  -actin (Sigma-Aldrich), or GP Ib  (clone
WM23; a gift from Michael C. Berndt, Monash University, Australia).
To study the binding of C3 to CHO cells, 105 cells (CHO-P or CHO)
cells were incubated in 0.5 ml PPP for 30 min. Cells were washed once and
were incubated with a 1:100 dilution of anti-C3 goat antiserum (Advanced
Research Technologies) for 30 min. Cells were washed once, and were
then incubated with FITC-conjugated secondary antibody (Zymed Labora-
tories). Samples were washed, and subsequently analyzed with a flow cy-
tometer (model EPICS XL; Coulter). Background fluorescence was set us-
ing normal goat serum (Pierce Chemical Co.) instead of the anti-C3
antiserum.
Formation of C5b-9 complex on activated platelets or heterolo-
gous cells. The presence of membrane attack complexes (C5b-9) on
platelets was studied by flow cytometry analysis using a rabbit polyclonal an-
tibody against a neoepitope of the C5b-9 complex (Advanced Research
Technologies). Approximately 106 TRAP-activated or resting platelets
were incubated with saturating concentrations of the anti-C5b-9 antibody,
and of a FITC-conjugated secondary antibody. Platelets were then diluted
with 1 ml TBS and analyzed by flow cytometry. For experiments using het-
erologous cells, CHO-P or CHO cells were incubated in PPP for 60 min at
37 C, and studied with flow cytometry using anti–C5b-9 antibody, as just
described for platelets.
Measurements of C3a. Formation of C3a was quantitated by BD
OptEIA ELISA for human C3a (BD PharMingen). 1 ml PRP (platelet
count, 250   103/ l) was stimulated with 20  M ADP, 5  M TRAP, or 5
 g/ml type-I collagen for 15 min at 37 C. Alternatively, 1 ml PRP was
subjected to various shear rates for 1 min, as described above. Platelets not
treated with any agonist and not subjected to shear served as the respective
controls. Futhan, an inhibitor of complement activation, was added (for a fi-
nal concentration of 50  g/ml) to the samples after stimulation to prevent
further C3a generation. In some experiments, neutrophils were isolated as
described previously (29) and resuspended in autologous plasma. They were
subsequently added to 100- l aliquots of 2   105/ l of autologous platelets
suspended in plasma to produce neutrophil counts ranging from 500 to 5  
105 neutrophils/ l PRP, and which was subsequently stimulated with 30
 g/ml of type-1 collagen for 30 min.
For measuring C3a generation by CHO cells, 106 cells were incubated
in 1 ml PPP for 60 min at 37 C. Futhan was added to the samples, the cells
were sedimented, and the plasma supernatant was collected and stored at
 80 C until assayed.
In other experiments, we measured C3a generation by CHO-P and
CHO cells using a reconstituted complement system in the presence or ab-
sence of factor B. 1.5   106 cells were suspended for 60 min at 37 C in TBS
with 1.5 mM CaCl2 and 1 mM MgCl2, supplemented with 600  g/ml puri-
fied human C3, 500 ng/ml factor D, and with or without 112.5  g/ml fac-
tor B. Cells were pelleted at 800 g for 5 min, the supernatant was collected
and treated with 50  g/ml futhan. C3a generation was measured by ELISA.
Binding of C3b to platelets and CHO cells. For assessing the binding
of C3b to cells, purified C3b (Advanced Research Technologies) was la-
beled with FITC using FluoReproter protein labeling kit (Molecular
Probes), according to the manufacturer’s protocol. 1 million TRAP-acti-
vated washed platelets or 105 CHO-P and CHO cells were incubated with
2   g/ml FITC-labeled C3b. Some experiments were performed in the
Figure 7. The proposed model P-selectin captures and immobilizes 
labile C3b. Binding of factor B to C3b initiates formation of C3 convertase 
(C3bBb) on the surface of activated platelet or endothelial cells. The C3 
convertase complex cleaves C3 and mediates amplification of the comple-
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presence or absence of 2 mM CaCl2 and 1 mM MgCl2, with or without 5
mM EDTA. Cell-associated fluorescence (defined by an FS-SS gate) was
measured with a flow cytometer.
Inhibition of C3b binding to activated platelet was investigated by in-
cubating washed platelets with 5  g/ml of rabbit polyclonal anti–P-selectin
antibody (BD PharMingen) before adding FITC-conjugated C3b.
Cleavage of surface proteins on activated platelets. We cleaved sur-
face proteins on activated platelets using protease K. Washed platelets were
activated with 10  M TRAP, as described before, and were then treated
with 50  g/ml protease K for 30 min, at room temperature. After washing
the platelets three times in 10 ml TBS, binding of FITC-conjugated C3b
was measured by flow cytometry, as described before.
Flow chamber studies. 30  g/ml of purified C3b was immobilized onto
glass coverslips by incubation at 37 C for 3 h. Coverslips were washed once
with buffer, and blocked with 1% BSA (Sigma-Aldrich). Coated coverslips
were mounted on the lower surface of a parallel plate flow chamber, as de-
scribed previously (30). The flow chamber was then mounted onto an in-
verted stage microscope (model Eclipse TE300; Nikon) equipped with an
image recording system. Platelets were activated with 5  M TRAP for 10
min at 37 C, in the presence or absence of 25  g/ml polyclonal anti–P-selec-
tin antibody (BD PharMingen) or an anti-GPIb  antibody (clone WM23; a
gift from M. Berndt, Monash University, Victoria, Australia), and were
then perfused through the chamber at a flow rate of 0.2 ml/min, generating
a wall shear stress of 2 dynes/cm2. Albumin-coated coverslips were used as
the controls.
Surface plasmon resonance binding assay. Surface plasmon reso-
nance binding studies were performed using a BIAcore 2000 system as pre-
viously described (31), with minor modifications. Recombinant human
P-selectin (50  g/ml in 50 mM sodium acetate, pH 4.8; R&D Systems) was
covalently coupled via amine coupling to a sensor chip (CM5) as directed
by the manufacturer (BIAcore). The immobilization of the P-selectin re-
sulted in  1,200 resonance units, corresponding to a surface density of  1
ng/mm2. The binding assays were performed in PBS, with 1 mM CaCl2
and 1 mM MgCl2, pH 7.4 at 25 C with a flow rate of 10  l/min. The
binding of the C3b to the P-selectin–coated channel was corrected for non-
specific binding to the control channel (no protein; between 5 and 10%).
P-Selectin binding at equilibrium was determined at several concentrations
of C3b (0.5, 1.0, 3.0, and 5.0  M). After measuring the C3b binding to
P-selectin, the chip was regenerated by injection of 1 mM EDTA, 1 M
NaCl, 0.1 M sodium citrate, pH 5.0, 10 mM deoxycholic acid, and 100
mM Tris, pH 9.0. The set of sensorgrams were best fit to the 1:1 Langmuir
binding model with drifting baseline using the BIAevaluation software (ver-
sion 3.0) provided by the manufacturer.
Statistics. All experiments were performed at least three times, each time
using the blood from different donors. Data throughout the paper are pre-
sented as mean   SD. Comparisons were made using Student’s t test; P  
0.05 was considered to be statistically significant.
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